Anthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL


Manage episode 304335672 series 9912
Van PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education, ontdekt door Player FM en onze gemeenschap - copyright toebehorend aan de uitgever, niet aan Player FM. Audio wordt direct van hun servers gestreamd. Klik de abonneren-knop aan om updates op Player FM te volgen of plak de feed URL op andere podcast apps.
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emergence of newer non-covalent BTK options. Throughout, our experts share sound, evidence-based treatment plans designed to address the medical needs of patients progressing on or unable to tolerate BTK covalent inhibitor therapy in the CLL/SLL and MCL settings. Upon completion of this accredited CE activity, participants should be better able to: Summarize current evidence on the mechanistic properties, safety, and efficacy of covalent and non-covalent BTK inhibitors with therapeutic applications in B-cell malignancies, including in settings where therapeutic intolerance or resistance mutations are present, Develop management models for capturing therapeutic intolerance or BTK resistance mutations at disease progression in patients receiving treatment with covalent BTK inhibitors, Recommend evidence-based management plans addressing the therapeutic and safety needs of patients with CLL/SLL or MCL who are progressing on a covalent BTK inhibitor with resistance mutations or who are unable to continue on therapy due to adverse events.

517 afleveringen